Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE: TEVA) and Medincell (Euronext: MEDCL) announced EMA acceptance of the Marketing Authorization Application for olanzapine long-acting injectable TEV-‘749 to treat adult schizophrenia.
The investigational subcutaneous injection is given every four weeks and is supported by a Phase 3 program, including SOLARIS.
TEV-‘749 uses Medincell’s SteadyTeq copolymer technology for controlled drug release and has shown efficacy, a systemic safety profile, and exposure consistent with oral olanzapine. TEV-‘749 is not approved by any regulatory authority worldwide.
Teva (NYSE:TEVA) and Medincell announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine long-acting injectable TEV-‘749 to treat schizophrenia in adults.
TEV-‘749 is a subcutaneous, once-every-four-weeks formulation supported by a Phase 3 program and is not yet approved anywhere.
Teva (NYSE:TEVA) reported that Fitch upgraded its corporate credit rating to investment grade BBB- with a stable outlook, up from BB+. Fitch also raised ratings on Teva’s senior unsecured debt and credit facilities to BBB-.
Fitch cites improved financial flexibility, a shift toward higher-margin innovative and biosimilar products, and expected growth driven by AUSTEDO, AJOVY, UZEDY and future launches such as olanzapine LAI, subject to regulatory approval. Teva remains rated BB+ (stable) by S&P and Ba1 (positive) by Moody’s.
Teva (NYSE:TEVA) reported new IMPACT-TD Registry data on adults with mood disorders and tardive dyskinesia (TD). Among young adults 18-29 (n=13), 85% had moderate to severe TD impact, yet only 23% were formally diagnosed, highlighting diagnostic gaps.
The 3-year, Phase 4, real-world registry includes 611 adults with TD; this analysis covered 211 with mood disorders not on VMAT2 inhibitors. Adults under 60 showed pronounced psychological effects, and patients waited on average over 3.5 years from first involuntary movements to TD diagnosis.
Teva (NYSE: TEVA) announced that Eric Hughes, EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Health Care Conference on May 12, 2026 at 9:20 A.M. PT / 12:20 P.M. ET. Live webcasts will stream from Teva’s investor relations site; archived webcasts will appear within 24 hours and remain available for up to 30 days.
Teva (NYSE: TEVA) published its 2025 Healthy Future Report highlighting sustainability and access-to-medicine achievements, including meeting all sustainability-linked bond targets totaling about $7.5 billion.
Key metrics: nearly 8 million people reached via product donations; 39% reduction in Scope 1–2 GHG since 2019; 32% reduction in Scope 3 since 2020; $36.4 billion in healthcare savings from generics across 21 countries; and >99% employee compliance training completion.
Teva (NYSE: TEVA) reported UZEDY U.S. net sales of $63 million in Q1 2026, up 62% year‑on‑year from $39 million and up 15% from $55 million in Q4 2025. Medincell receives mid‑ to high‑single‑digit royalties on UZEDY and may earn up to $105M in commercial milestones tied to annual sales thresholds. UZEDY is a 1‑ and 2‑month subcutaneous risperidone LAI approved in the U.S. for schizophrenia (Apr 2023) and Bipolar I Disorder (Oct 2025). Teva’s NDA for once‑monthly olanzapine LAI was accepted in Feb 2026; U.S. decision expected Q4 2026 and European MAA acceptance expected Q2 2026.
Teva (NYSE:TEVA) reported Q1 2026 revenue of $3,982 million, up 2% in U.S. dollars and down 3% in local currency. Key innovative brands grew strongly (AUSTEDO $578M, AJOVY $196M, UZEDY $63M) while generics declined; PONLIMSI received FDA approval and Teva agreed to acquire Emalex, expected to close by Q3 2026.
GAAP diluted EPS $0.31; non-GAAP diluted EPS $0.53; free cash flow $188 million; 2026 outlook maintained and updated for Emalex.
Teva (NYSE:TEVA) will acquire Emalex Biosciences for $700 million upfront, plus up to $200 million in commercial milestones and royalties on global net sales of ecopipam, subject to regulatory approval. Ecopipam is an NDA-ready, first-in-class selective D1 antagonist for pediatric Tourette syndrome with FDA Orphan Drug and Fast Track designations and positive Phase 3 primary endpoint results; NDA submission is anticipated in 2H 2026. The deal is expected to close by Q3 2026, funded from Teva cash on hand, and Teva said it will seek to mitigate near-term margin dilution while remaining on track for its 2027 targets.
Teva (NYSE: TEVA) launched Home Ground™ Schizophrenia Community on April 15, 2026, an online, no‑cost platform offering peer‑informed resources, symptom‑tracking tools, emotional‑wellness content, independent‑living guides, physical‑health prompts and event listings to support people living with schizophrenia and their care partners.
Content was developed with input from people living with schizophrenia, care partners and advocacy groups to reduce isolation and augment clinical care.